Physician profile
Taylor Lee
NPI 1578227658
$639.60
in general payments reported to CMS, 2019-2025
14 companies · $39.00 in 2025
The $39.00 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.91 · 2022: $264 · 2023: $150 · 2024: $122 · 2025: $39.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $311.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $127.20 | 2022-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $108.98 | 2021-2024 | Caplyta |
| Kaleo, INC. | $75.98 | 2021-2022 | |
| Alkermes, INC. | $66.92 | 2022-2024 | Aristada, Lybalvi |
| Lundbeck LLC | $62.34 | 2022-2023 | Abilify Maintena |
| Abbvie INC. | $59.27 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $29.82 | 2024 | Qelbree |
| Vertical Pharmaceuticals, LLC | $18.92 | 2024 | Relexxii |
| Axsome Therapeutics, INC. | $17.39 | 2023 | Auvelity |
| Collegium Pharmaceutical, INC. | $16.27 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $14.64 | 2024 | |
| Indivior INC. | $14.42 | 2023 | Perseris |
| Teva Pharmaceuticals USA, INC. | $14.21 | 2023 | Austedo |
| Neurocrine Biosciences, INC. | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.